18F-FDGPET／CT对非小细胞肺癌治疗后纵隔淋巴结转移再分期的价值

目的应用18F—FDGPET／CT为手术或放化疗后非小细胞肺癌（NSCLC）患者进行再分期，以评价18F—FDGPET／CT在诊断纵隔淋巴结转移的价值。方法本组受检者51例（男41例，女10例），年龄34—90岁（平均61．86±12．81岁）。鳞癌29例，腺癌20例，腺鳞癌2例。根据文献中接收器工作特性分析确定良恶性结节阈值截点SUV值〉3．5为阳性淋巴结。结果51例患者中45例检出纵隔淋巴结，SUV值〉3．5的阳性淋巴结共有63％（79／125），SUV值〉3．5且小于1cm结节35％（28／79），SUV值〉3．5且大于1cm结节65％（51／79）。肺腺癌20例中阳性淋巴结58％（46／79），鳞癌29例中阳性淋巴结41％（32／79），腺鳞癌2例中阳性淋巴结1％（1／79）。肺腺癌和鳞癌患者小于1cm和大于1cm的阳性淋巴结数量的差异有统计学意义（x2=18．25，P〈0．05）。结论18F—FDGPET／CT对NSCLC治疗后纵隔淋巴结转移的再分期有较大价值。

Value of 18F-FDG PET/CT for restaging metastasis of mediastinal lymph nodes in patients with non-small cell lung cancer

Objective To evaluate the value of 18 fluorodeoxyglucose（FDG） positron emission tomography and computed tomography（PET/CT） for restaging metastasis of mediastinal lymph nodes in patients with non-small cell lung cancer（NSCLC） after treatment. Methods Of the 51 NSCLC patients（41 men and 10 women） at a mean age of 61 years（range 34-90 years） included in this study, 29 had squamous carcinoma, 20 had adenocarcinoma, and 2 had adenosquamous carcinoma. If the SUV threshold cutoff was 〉3.5 according to prior receiver operating characteristic analysis, the lymph nodes were defined as positive. Results Mediastinal lymph nodes were detected in 45 of the 51 patients. The SUV value was 〉3.5 in 63%（79/125） lymph nodes, in 35%（28/79） lymph nodes less than lcm in diameter, and in 65%（51/79） lymph nodes greater than lcm in diameter, respectively. The positive rate of lymph nodes was 58%（46/79）, 41%（32/79）, and 1%（1/79）in 20 patients with lung adenocarcinoma, in 29 patients with squamous carcinoma, and in 2 patients with adenosquamous carcinoma, respectively. No difference was found in the number of lymph nodes less or greater than lcm in diameter between patients with lung adenocarcinoma and those with squamous carcinoma（ x2=18.25, P〈0.05）. Conclusion 18F-FDG PET/CT has a high predictive value for restaging metastasis of mediastinal lymph nodes in NSCL patients.